Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 years of age or older~* Main active disease of the ileal, ileocecal region, and/or ascending colon - - If treated with partial nutrition treatment (≤1200 kcal/day) or if treated with azathioprine (≤2.0 mg/kg/day) or 6-mercaptopurine (≤1.2 mg/kg/day), prior to randomisation until the study completion or discontinuation~* Ability to read, write and to fill a diary card and HRQL questionnaire Having mild to moderate active Crohn's disease, defined as CDAI score of 180-400 at baseline~Exclusion Criteria:~* Patient with CD lesion or status which may affect the evaluation of the efficacy (e.g. lesion only in the upper G-I, active anorectal lesion, abscess formation, stenosis, fistulae, ostomy, short bowel or other uncontrolled concomitant disease)~* Patient who need any concomitant treatment for CD that may affect the assessment for efficacy of the study drug~* Patient who need any medication which is prohibited due to suspected influence to metabolism of the study drug~* Patient who is judged to be inadequate to participate in this study from the safety point of view Patient with well-founded doubt about protocol violation

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- D9421-C (Type: EXPERIMENTAL): D9421-C 9 mg once daily
- Mesalazine (Type: ACTIVE_COMPARATOR): Mesalazine 1 g three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).